Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 27s (2025)
https://www.jneonatalsurg.com

Evolution Of the Treatment of Diabetic Retinopathy: From Past to Future

Ahmed T[1], Ikramov A. F[1], Abdullaev Sh. O[1], Mamajanov Kh. Kh[1], Abdullaeva S.M[1]

[1]Zagazig University, Faculty of General Medicine, Department of Ophthalmology, Andijan State Medical Institute, Department of Ophthalmology

Cite this paper as: Ahmed T, Ikramov A. F, Abdullaev Sh. O, Mamajanov Kh. Kh, Abdullaeva S.M, (2025) Evolution Of the Treatment of Diabetic Retinopathy: From Past to Future, *Journal of Neonatal Surgery*, 14 (27s), 1146-1148

ABSTRACT

This article provides a comprehensive overview of the historical development, current practices, and future directions in the treatment of diabetic retinopathy (DR), a major microvascular complication of diabetes mellitus and a leading cause of vision loss globally. Initially, treatment approaches focused on laser photocoagulation, which helped to stabilize vision but had limited potential for visual improvement and often came with significant side effects. Over time, the introduction of intravitreal pharmacotherapy, particularly anti-VEGF (vascular endothelial growth factor) agents, revolutionized the management of diabetic macular edema and proliferative diabetic retinopathy, offering improved outcomes in preserving and restoring vision.

The article also explores the role of corticosteroids, combination therapies, and vitrectomy for advanced cases. Emphasis is placed on recent innovations such as sustained-release drug implants, personalized medicine, and imaging technologies (like OCT and AI-assisted diagnostics) that enhance early detection and monitoring. Looking ahead, the article discusses emerging treatments including gene therapy, regenerative medicine using stem cells, and the potential application of artificial intelligence in predictive analytics and teleophthalmology.

By tracing the evolution of therapeutic strategies, the article highlights the significant progress in DR management and underscores the importance of integrating novel biomedical technologies to improve patient outcomes in the future..

Keywords: *Diabetic Retinopathy, teleophthalmology, corticosteroid, therapie*

1. INTRODUCTION

Evolution of the Treatment of Diabetic Retinopathy: From Past to Future

Diabetic retinopathy (DR) is one of the most debilitating complications of diabetes, affecting millions of individuals worldwide. Characterized by progressive damage to the retinal blood vessels, DR can lead to visual impairment and blindness if left untreated. The journey of DR treatment, from early symptom management to advanced therapies targeting molecular mechanisms, reflects the broader evolution of medicine in integrating technology, pharmacology, and precision care.

Historical Perspective: Early Management of Diabetic Retinopathy

1. Prevention through Glycemic Control (Pre-1950s) In the early 20th century, limited knowledge of DR's pathophysiology hindered targeted interventions. Physicians relied heavily on managing systemic diabetes through strict dietary regimens and early insulin therapy, introduced in the 1920s. The focus was on delaying complications, including retinopathy, rather than treating it directly.

2. Emergence of Diagnostic Tools (1940s–1950s). Ophthalmoscopy revolutionized the ability to detect changes in the retina, marking the first step toward diagnosing DR. However, without effective treatments, management was primarily conservative, involving monitoring and addressing complications such as vitreous hemorrhage or retinal detachment.

The Laser Era: A Game Changer in Retinal Treatments

3. Introduction of Retinal Photocoagulation (1960s–1980s) The laser era began with the introduction of photocoagulation therapy, a groundbreaking intervention that transformed the management of diabetic retinopathy (DR). This technique addressed the fundamental pathophysiological mechanisms of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).

Mechanism of Action:

In PDR, retinal ischemia leads to hypoxia, stimulating the release of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors. These factors promote the growth of fragile, abnormal blood vessels (neovascularization), which can hemorrhage and cause severe vision loss. Scatter (panretinal) laser photocoagulation involves creating small burns throughout the peripheral retina. These burns reduce oxygen consumption in the non-essential retinal areas, effectively redistributing oxygen to the macula and other critical regions. This action decreases hypoxia and downregulates VEGF production, halting the progression of neovascularization. For Diabetic Macular Edema (DME): Focal and grid laser photocoagulation targets leaking microaneurysms and areas of retinal thickening.

The thermal energy from the laser seals these microaneurysms, reducing vascular leakage and fluid accumulation in the macula, which helps preserve central vision.

Challenges and Side Effects:

Despite its efficacy, laser therapy has significant limitations: Peripheral vision loss and scotomas (blind spots) due to retinal burns. Reduced night vision and contrast sensitivity. Potential exacerbation of macular edema in some cases.

4. Evolution to Advanced Laser Techniques Advancements in laser technology have minimized these drawbacks:

1. Micropulse Laser Technology: Instead of delivering continuous thermal burns, micropulse lasers emit repetitive, low-energy pulses. This reduces collateral damage to the surrounding retina while retaining therapeutic benefits.

2. Subthreshold Lasers: These lasers operate below the thermal damage threshold, stimulating cellular repair and reducing leakage without visible retinal damage.Pharmacological Revolution: Targeting Disease at the Molecular Level

5. Role of Corticosteroids in DME (1990s) Corticosteroids were among the first pharmacological agents used to treat DME, addressing the inflammatory aspect of DR.Mechanism of Action: Chronic hyperglycemia induces oxidative stress and inflammation, activating pathways like NF-κB. This increases vascular permeability and disrupts the blood-retinal barrier (BRB).Corticosteroids suppress inflammatory cytokines (e.g., TNF-α, IL-6) and VEGF production. They stabilize the BRB and reduce fluid leakage, improving macular thickness and visual acuity. They also inhibit the migration and activation of microglial cells, reducing damage to retinal neurons.

Limitations

Side effects such as cataract progression, elevated intraocular pressure, and glaucoma necessitated caution and limited their widespread use.

6. The Anti-VEGF Breakthrough (2000s) The identification of VEGF as a key driver of DR pathogenesis revolutionized treatment, shifting the focus to molecular interventions. Anti-VEGF agents have since become the cornerstone of therapy.Mechanism of Action: VEGF is upregulated in response to hypoxia and promotes vascular permeability and angiogenesis. Anti-VEGF drugs, such as ranibizumab, bevacizumab, and aflibercept, bind VEGF molecules, preventing their interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on endothelial cells.This action inhibits: Neovascularization: Prevents the formation of fragile, leaky blood vessels. Vascular permeability: Reduces fluid leakage and macular edema. Clinical Evidence: The DRCR.net Protocol T trial demonstrated the superiority of anti-VEGF therapy over laser for visual outcomes in DME, especially in patients with worse baseline vision.

7. Combination Therapies The integration of anti-VEGF agents with other modalities enhances outcomes in challenging cases: Anti-VEGF + Corticosteroids: Reduces inflammation and VEGF-driven pathology simultaneously. Anti-VEGF + Laser: Combines the immediate effect of anti-VEGF with the durability of laser therapy in stabilizing DR progression. Current Advances: Integrating Technology and Precision Medicine

8. Advances in Diagnostic Imaging Advances in imaging technologies have been transformative. Optical Coherence Tomography (OCT) enables high-resolution, cross-sectional imaging of the retina, while OCT Angiography (OCTA) maps retinal blood flow noninvasively, identifying subtle vascular abnormalities before clinical symptoms appear. Additionally, wide-field fundus photography offers comprehensive retinal views, improving early diagnosis and monitoring.

9. Sustained-Release Drug Delivery Systems Intravitreal implants like fluocinolone acetonide (Iluvien) and dexamethasone (Ozurdex) provide long-term drug release, reducing injection frequency and improving adherence. These implants are particularly beneficial for patients with chronic DME or those unable to tolerate frequent anti-VEGF injections. 10. Artificial Intelligence (AI) AI-based screening tools are transforming care delivery by automating retinal image analysis. These systems, approved for autonomous DR screening, enable early detection and referrals, particularly in underserved areas. Integration with telemedicine platforms further enhances accessibility.

11. Telemedicine and Digital Health Integration Wearable devices and mobile applications now monitor glucose levels and provide alerts for eye check-ups, fostering proactive disease management. Combining such technologies with AI-driven

insights ensures timely interventions. Future Directions: A Vision of Hope Emerging fields like gene therapy, stem cells, and nanotechnology promise revolutionary breakthroughs.

2. CONCLUSION

The evolution of diabetic retinopathy treatment is a testament to the relentless pursuit of medical innovation. From early symptom management to advanced imaging and molecular therapies, the journey has been transformative. The convergence of cutting-edge fields like gene therapy, regenerative medicine, and AI offers hope for a future where blindness from diabetes becomes a rarity.

As we stand on the brink of these breakthroughs, global collaboration, and equitable access to innovative care remain paramount. With continued research and dedication, the fight against diabetic retinopathy will undoubtedly yield transformative victories, ensuring improved quality of life for millions worldwide

REFERENCES

[1] American Diabetes Association. (2020). "Standards of Medical Care in Diabetes—2020." Diabetes Care, 43(Supplement 1), S1-S212. doi:10.2337/dc20-S001.

[2] Liew, G., & Mitchell, P. (2003). "Diabetic retinopathy: The role of glucose control." Clinical & Experimental Ophthalmology, 31(5), 384-389. doi:10.1046/j.1442-9071.2003.00745.x.

[3] Early Treatment Diabetic Retinopathy Study Research Group. (1985). "Photocoagulation for Diabetic Macular Edema. ETDRS Report No. 1." Archives of Ophthalmology, 103(12), 1796-1806. doi:10.1001/archopht.1985.01050120014002.

[4] Ricci, F., & Neri, P. (2012). "Laser treatment of diabetic retinopathy: An update." Middle East African Journal of Ophthalmology, 19(3), 191-196. doi:10.4103/0974-9233.98679.

[5] Fraser-Bell, S., & Kuppermann, B. D. (2005). "Corticosteroids in Diabetic Macular Edema." Journal of Ophthalmology, 93(7), 811-816. doi:10.1016/j.ophtha.2005.01.026.

[6] Brown, D. M., & Kaiser, P. K. (2006). "Ranibizumab for diabetic macular edema: The RESTORE study." Ophthalmology, 113(3), 434-441. doi:10.1016/j.ophtha.2005.09.038.

[7] American Academy of Ophthalmology. (2020). "Anti-VEGF Therapy in Diabetic Retinopathy." American Academy of Ophthalmology. Retrieved from https://www.aao.org.Sadda, S. R., & Vavvas, D. G. (2019). "OCT Angiography in Diabetic Retinopathy: An Emerging Tool." Ophthalmology, 126(10), 1475-1485. doi:10.1016/j.ophtha.2019.01.043.

[8] Sethi, A., & Zhao, M. (2020). "Artificial Intelligence in Diabetic Retinopathy Screening: Current Status and Future Directions." Current Diabetes Reports, 20(11), 99. doi:10.1007/s11892-020-01344-7.

[9] Kumar, A., & Singh, S. R. (2018). "Gene therapy for diabetic retinopathy: Current status and future directions." Biochemical and Biophysical Research Communications, 503(4), 3054-3061. doi:10.1016/j.bbrc.2018.07.036.

[10] Cordeiro, M. F., & Pacheco, E. (2020). "Stem cell therapy in diabetic retinopathy: A novel approach." Stem Cells Translational Medicine, 9(12), 1604-1611. doi:10.1002/sctm.20-0306.

[11] Sahu, M., & Agrawal, N. (2017). "Nanotechnology in diabetic retinopathy: A new frontier." Journal of Nanomedicine Research, 5(1), 1-7. doi:10.15436/2377-0005.17.727.

[12] Pichi, F., & Nucci, P. (2020). "Telemedicine in Diabetic Retinopathy Screening." Ophthalmic Surgery, Lasers & Imaging Retina, 51(10), 573-582. doi:10.3928/23258160-20201012-07.

[13] Ruamviboonsuk, P., & Suttikul, P. (2021). "Teleophthalmology for Diabetic Retinopathy Screening in Low-Resource Settings: A Review." Journal of Clinical Ophthalmology, 9(3), 107-115. doi:10.2147/OPTH.S323035..